Cargando…

Silymarin therapy and improvement of cardiac outcome in patients with β-thalassemia major

Detalles Bibliográficos
Autores principales:	Khezri, Hadi Darvishi, Kosaryan, Mehrnoush, Salehifar, Ebrahim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776552/ https://www.ncbi.nlm.nih.gov/pubmed/26985440 http://dx.doi.org/10.4103/2279-042X.176555

Ejemplares similares

Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015
por: Darvishi Khezri, Hadi, et al.
Publicado: (2016)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension
por: Karami, Hossein, et al.
Publicado: (2018)

Treatment Status of Patients with B-Thalassemia Major in Northern Iran: Thalassemia Registry System
por: KOSARYAN, Mehrnoush, et al.
Publicado: (2019)

Amlodipine: Can act as an antioxidant in patients with transfusion‐dependent β‐thalassemia? A double‐blind, controlled, crossover trial
por: Darvishi‐Khezri, Hadi, et al.
Publicado: (2022)

Ferritin thresholds for cardiac and liver hemosiderosis in β-thalassemia patients: a diagnostic accuracy study
por: Darvishi-Khezri, Hadi, et al.
Publicado: (2022)

Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy
por: Darvishi-Khezri, Hadi, et al.
Publicado: (2018)

Moderate to severe liver siderosis and raised AST are independent risk factors for vitamin D insufficiency in β-thalassemia patients
por: Darvishi-Khezri, Hadi, et al.
Publicado: (2020)

Serum Lipids in Turkish Patients with β-Thalassemia Major and β-Thalassemia Minor
por: Işık Balcı, Yasemin, et al.
Publicado: (2016)

Ebselen: A promising therapy protecting cardiomyocytes from excess iron in iron-overloaded thalassemia patients
por: Ghazaiean, Mobin, et al.
Publicado: (2023)

MRI Evaluation of Liver Iron Concentration in Patients with β-Thalassemia Major
por: Karimi, M, et al.
Publicado: (2010)

Pain in β-thalassemia major patients: an important yet neglected issue
por: Zeydi, Amir Emami, et al.
Publicado: (2018)

Is the HIV Seroprevalence among Iraqi Patients with β-thalassemia Major Underestimated or not Prevalent?
por: Al-Mendalawi, Mahmood Dhahir
Publicado: (2021)

In Vitro Hb Production in B-thalassemia Patients Is Not a Predictor of Clinical Responsiveness to Hydroxyurea
por: MAHDAVI, Mohammad Reza, et al.
Publicado: (2017)

Iron overload assessment in β Thalassemia Major – is T2* Magnetic Resonance Imaging the answer?
por: Ali, Natasha
Publicado: (2017)

Extramedullary Hematopoiesis Presenting as a Right Adrenal Mass in a Patient With Beta Thalassemia
por: Karami, Hossein, et al.
Publicado: (2014)

Iron overload and fragmented QRS in patients with Thalassemia major: Mechanisms, therapies, and new horizons
por: Karakulak, Uğur Nadir, et al.
Publicado: (2015)

Analysis of (G)γ-158(C→T) polymorphism in hemoglobin E/β-thalassemia major in Southern China
por: Liu, Rong Rong, et al.
Publicado: (2010)

Right Ventricular Diastolic Function in Patients with Thalassemia Major
por: Demirkol, Sait, et al.
Publicado: (2013)

Significant Differences in Thymic Index of Thalassemia Major Patients
por: Oymak, Yeşim, et al.
Publicado: (2014)

Genetic Variation Impacts in Patients with Major Beta-Thalassemia
por: NAJAF POUR, Maliheh, et al.
Publicado: (2015)

Comment on: "Economic Burden of Thalassemia Major in Iran, 2015"
por: Rezaei, Satar, et al.
Publicado: (2016)

Therapeutic potential of silymarin as a natural iron‐chelating agent in β‐thalassemia intermedia
por: Reisi, Nahid, et al.
Publicado: (2022)

Reticulocytes indices in β thalassemia trait individuals
por: Wagner, Sandrine Comparsi, et al.
Publicado: (2011)

Silymarin: An option to treat non-alcoholic fatty liver disease
por: Colica, Carmela, et al.
Publicado: (2017)

The Protective Role of Silymarin and Aerobic Exercise on Gentamicin-induced Nephrotoxicity
por: Alavijeh, Fatemeh Shafiei, et al.
Publicado: (2019)

Does Testosterone Replacement Therapy Promote an Augmented Risk of Thrombotic Events in Thalassemia Major Male Patients with Hypogonadism?
por: De Sanctis, Vincenzo, et al.
Publicado: (2017)

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia
por: Hagag, Adel A., et al.
Publicado: (2013)

HB E/β°Thalassemia can present with normal phenotype
por: Pal, Ranabir, et al.
Publicado: (2010)

Low HbA2 Level in β-Thalassemia Trait
por: ÖZSOYLU, Şinasi
Publicado: (2013)

Sex-specific transcriptional profiles identified in β-thalassemia patients
por: Nanou, Aikaterini, et al.
Publicado: (2021)

Current practice in treating adult female thalassemia major patients with hypogonadism: An International Network of Clinicians for Endocrinopathies in Thalassemia and Adolescence Medicine survey from Italy
por: De Sanctis, Vincenzo, et al.
Publicado: (2016)

Did the Proband Have Thalassemia Intermedia or Severe Thalassemia Trait?
por: Özsoylu, Şinasi
Publicado: (2012)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Late-onset Male Hypogonadism and Fertility Potential in Thalassemia Major Patients: Two Emerging Issues
por: De Sanctis, Vincenzo, et al.
Publicado: (2015)

Hematological malignancies complicating β-thalassemia syndromes: a single center experience
por: Alavi, Samin, et al.
Publicado: (2013)

Sickle cell-β thalassemia with concomitant hemophilia A: a rare presentation
por: Dhiman, Pratibha, et al.
Publicado: (2015)

Formulas for the Detection β-Thalassemia Carriers Are Affected by Changes in Red Cell Parameters
por: Aslan, Deniz
Publicado: (2018)

Two Rare Pathogenic HBB Variants in a Patient with β-Thalassemia Intermedia
por: Hançer, Veysel Sabri, et al.
Publicado: (2020)

ß-thalassemia and alkaptonuria
por: Yasri, Sora, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tdo4fuhtnab0g4me2ncd05fh89